NDAORALTABLETPriority Review
Approved
Nov 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TONOCARD (tocainide hydrochloride) is an oral Class IB antiarrhythmic agent approved in 1984 for the treatment of ventricular arrhythmias. It is a lidocaine analog that suppresses ectopic activity by blocking sodium channels in cardiac tissue. The drug is indicated for patients with documented ventricular arrhythmias who require suppression.
LOE Approaching
LOE approaching with moderate competitive pressure (30%) signals a mature, legacy product likely managed by a small, efficiency-focused team focused on retention rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TONOCARD offers limited career growth potential given its LOE-approaching lifecycle and minimal linked job opportunities. Positions on this legacy product are typically focused on compliance, market maintenance, and operational efficiency rather than innovation or team expansion.
Brand ManagerMedical Science Liaison
Worked on TONOCARD at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.